Literature DB >> 18360291

The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men.

David Wohl1, Rebecca Scherzer, Steven Heymsfield, Michael Simberkoff, Stephen Sidney, Peter Bacchetti, Carl Grunfeld.   

Abstract

BACKGROUND: HIV infection and antiretroviral therapy are associated with dyslipidemia, but the association between regional adipose tissue depots and lipid levels is not defined.
METHODS: The association of magnetic resonance imaging-measured visceral adipose tissue (VAT) and regional subcutaneous adipose tissue (SAT) volume with fasting lipid parameters was analyzed by multivariable linear regression in 737 HIV-infected and 145 control men from the study of Fat Redistribution and Metabolic Change in HIV Infection.
RESULTS: HIV-infected men had higher median triglycerides (170 mg/dL vs. 107 mg/dL; P < 0.0001), lower high-density lipoprotein cholesterol (HDL-C; 38 mg/dL vs. 46 mg/dL; P < 0.0001), and lower low-density lipoprotein cholesterol (LDL-C; 105 mg/dL vs. 125 mg/dL; P < 0.0001) than controls. After adjustment, greater VAT was associated with higher triglycerides and lower HDL-C in HIV-infected and control men, whereas greater leg SAT was associated with lower triglycerides in HIV-infected men with a similar trend in controls. More upper trunk SAT was associated with higher LDL-C and lower HDL-C in controls, whereas more lower trunk SAT was associated with higher triglycerides in controls. After adjustment, HIV infection remained strongly associated (P < 0.0001) with higher triglycerides (+76%, 95% confidence interval [CI]: 53 to 103), lower LDL-C (-19%, 95% CI: -25 to -12), and lower HDL-C (-18%, 95% CI: -22 to -12).
CONCLUSIONS: HIV-infected men are more likely than controls to have higher triglycerides and lower HDL-C, which promote atherosclerosis, but also lower LDL-C. Less leg SAT and more VAT are important factors associated with high triglycerides and low HDL-C in HIV-infected men. The reduced leg SAT in HIV-infected men with lipoatrophy places them at increased risk for proatherogenic dyslipidemia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18360291      PMCID: PMC3156607          DOI: 10.1097/QAI.0b013e31816d9ba1

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  38 in total

1.  Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients.

Authors:  Eugenia Negredo; Josep Ribalta; Raimon Ferré; Juliana Salazar; Celestino Rey-Joly; Guillem Sirera; Lluís Masana; Bonaventura Clotet
Journal:  AIDS       Date:  2004-03-26       Impact factor: 4.177

2.  Anthropometrics and examiner-reported body habitus abnormalities in the multicenter AIDS cohort study.

Authors:  Frank J Palella; Stephen R Cole; Joan S Chmiel; Sharon A Riddler; Barbara Visscher; Adrian Dobs; Carolyn Williams
Journal:  Clin Infect Dis       Date:  2004-03-01       Impact factor: 9.079

3.  Lipodystrophy with hyperlipidaemia: the role of insulin in very low density lipoprotein over-synthesis.

Authors:  A Chait; E Janus; A S Mason; B Lewis
Journal:  Clin Endocrinol (Oxf)       Date:  1979-02       Impact factor: 3.478

4.  Recruitment in the Coronary Artery Disease Risk Development in Young Adults (Cardia) Study.

Authors:  G H Hughes; G Cutter; R Donahue; G D Friedman; S Hulley; E Hunkeler; D R Jacobs; K Liu; S Orden; P Pirie
Journal:  Control Clin Trials       Date:  1987-12

5.  Familial lipoatrophic diabetes with dominant transmission. A new syndrome.

Authors:  M G Dunnigan; M A Cochrane; A Kelly; J W Scott
Journal:  Q J Med       Date:  1974-01

6.  Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile.

Authors:  M van der Valk; J J Kastelein; R L Murphy; F van Leth; C Katlama; A Horban; M Glesby; G Behrens; B Clotet; R K Stellato; H O Molhuizen; P Reiss
Journal:  AIDS       Date:  2001-12-07       Impact factor: 4.177

7.  Metabolic effects of indinavir in healthy HIV-seronegative men.

Authors:  M A Noor; J C Lo; K Mulligan; J M Schwarz; R A Halvorsen; M Schambelan; C Grunfeld
Journal:  AIDS       Date:  2001-05-04       Impact factor: 4.177

8.  Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study.

Authors:  Phyllis C Tien; Stephen R Cole; Carolyn Masters Williams; Rui Li; Jessica E Justman; Mardge H Cohen; Mary Young; Nancy Rubin; Michael Augenbraun; Carl Grunfeld
Journal:  J Acquir Immune Defic Syndr       Date:  2003-12-15       Impact factor: 3.731

9.  The metabolic effects of lopinavir/ritonavir in HIV-negative men.

Authors:  Grace A Lee; Tara Seneviratne; Mustafa A Noor; Joan C Lo; Jean-Marc Schwarz; Francesca T Aweeka; Kathleen Mulligan; Morris Schambelan; Carl Grunfeld
Journal:  AIDS       Date:  2004-03-05       Impact factor: 4.177

10.  CARDIA: study design, recruitment, and some characteristics of the examined subjects.

Authors:  G D Friedman; G R Cutter; R P Donahue; G H Hughes; S B Hulley; D R Jacobs; K Liu; P J Savage
Journal:  J Clin Epidemiol       Date:  1988       Impact factor: 6.437

View more
  53 in total

Review 1.  Dyslipidemia and its Treatment in HIV Infection.

Authors:  Carl Grunfeld
Journal:  Top HIV Med       Date:  2010 Aug-Sep

2.  Intermuscular adipose tissue and metabolic associations in HIV infection.

Authors:  Rebecca Scherzer; Wei Shen; Steven B Heymsfield; Cora E Lewis; Donald P Kotler; Mark Punyanitya; Peter Bacchetti; Michael G Shlipak; Carl Grunfeld
Journal:  Obesity (Silver Spring)       Date:  2010-06-10       Impact factor: 5.002

3.  Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.

Authors:  Takara L Stanley; Julian Falutz; Jean-Claude Mamputu; Graziella Soulban; Diane Potvin; Steven K Grinspoon
Journal:  AIDS       Date:  2011-06-19       Impact factor: 4.177

Review 4.  Management of the metabolic effects of HIV and HIV drugs.

Authors:  Todd T Brown; Marshall J Glesby
Journal:  Nat Rev Endocrinol       Date:  2011-09-20       Impact factor: 43.330

5.  Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy.

Authors:  Carl Grunfeld; Michael Saag; Joseph Cofrancesco; Cora Elizabeth Lewis; Richard Kronmal; Steven Heymsfield; Phyllis C Tien; Peter Bacchetti; Michael Shlipak; Rebecca Scherzer
Journal:  AIDS       Date:  2010-07-17       Impact factor: 4.177

Review 6.  Endocrinological aspects of HIV infection.

Authors:  F S Mirza; P Luthra; L Chirch
Journal:  J Endocrinol Invest       Date:  2018-01-08       Impact factor: 4.256

7.  The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia.

Authors:  Kathleen Mulligan; Hootan Khatami; Jean-Marc Schwarz; Giorgos K Sakkas; Alex M DePaoli; Viva W Tai; Michael J Wen; Grace A Lee; Carl Grunfeld; Morris Schambelan
Journal:  J Clin Endocrinol Metab       Date:  2009-01-27       Impact factor: 5.958

8.  Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection.

Authors:  Graeme J Moyle; Hélène Hardy; Awny Farajallah; Michelle DeGrosky; Donnie McGrath
Journal:  Clin Drug Investig       Date:  2014-04       Impact factor: 2.859

9.  HIV infection and the risk of acute myocardial infarction.

Authors:  Matthew S Freiberg; Chung-Chou H Chang; Lewis H Kuller; Melissa Skanderson; Elliott Lowy; Kevin L Kraemer; Adeel A Butt; Matthew Bidwell Goetz; David Leaf; Kris Ann Oursler; David Rimland; Maria Rodriguez Barradas; Sheldon Brown; Cynthia Gibert; Kathy McGinnis; Kristina Crothers; Jason Sico; Heidi Crane; Alberta Warner; Stephen Gottlieb; John Gottdiener; Russell P Tracy; Matthew Budoff; Courtney Watson; Kaku A Armah; Donna Doebler; Kendall Bryant; Amy C Justice
Journal:  JAMA Intern Med       Date:  2013-04-22       Impact factor: 21.873

10.  Epicardial fat is associated with duration of antiretroviral therapy and coronary atherosclerosis.

Authors:  Michael Brener; Kerunne Ketlogetswe; Matthew Budoff; Lisa P Jacobson; Xiuhong Li; Panteha Rezaeian; Aryabod Razipour; Frank J Palella; Lawrence Kingsley; Mallory D Witt; Richard T George; Wendy S Post
Journal:  AIDS       Date:  2014-07-17       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.